Dalbavancin use in an academic medical centre and associated cost savings

Amber C. Streifel, Monica K. Sikka, Christina D. Bowen, James S. Lewis

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Dalbavancin is a lipoglycopeptide antibiotic with unique weekly dosing active against Gram-positive organisms. This retrospective study included 37 patients receiving a mean of 2.7 weeks of dalbavancin. Nine patients (24%) were re-admitted to the hospital within 30 days. A total of 617 hospital days were saved, estimated to result in US$1 495 336 in savings and a mean cost avoidance of US$40 414 per patient. Dalbavancin provides a valuable antibiotic option that may minimise healthcare expenditure.

Original languageEnglish (US)
Pages (from-to)652-654
Number of pages3
JournalInternational Journal of Antimicrobial Agents
Issue number5
StatePublished - Nov 2019


  • Dalbavancin
  • Gram-positive infection
  • OPAT
  • Outpatient parenteral antimicrobial therapy

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Dalbavancin use in an academic medical centre and associated cost savings'. Together they form a unique fingerprint.

Cite this